Study of Karenitecin (BNP1350) in Patients With Brain Tumors

Completed · Phase 2

Conditions studied: Brain Neoplasms, Malignant Neoplasms, Brain, Brain Tumors

In brief

The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.

Key facts

Study ID

NCT00062478

Run by

BioNumerik Pharmaceuticals, Inc.

People needed

40

Starts

2001-10-01

Last updated by the study team

2020-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• For Information call 210-614-1701 for a site near you — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.